At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 942 enrolled
Drug / intervention
Dexpramipexole +1 moredrug
Likely dose
Dexpramipexole 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis
In Brief
A Phase 3 clinical trial evaluating Dexpramipexole and Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 942 participants across 82 sites in 11 countries.
Detailed Summary
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesAustralia, Belgium, Canada, France, Germany, Ireland, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartMar 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedJan 21, 2011
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.4 years ago
Interventions
Dexpramipexoledrug
Oral tablet 150mg twice daily for up to 18 months.
Placebodrug
Oral tablet twice daily for up to 18 months.